PROVISION OF TUMOUR PROFILING TEST

Official notice

Authority: CORNWALL PARTNERSHIP NHS FOUNDATION TRUST (Central government)

GoodsAward procedure without prior publication of a call for competition

Sectors: Medical Devices & Pharma (33) Delivery: South West (UKK42)

Awarded value£121,500published contract · exc. VAT

Awarded 17 Mar 2022no call for competition

Awarded to Exact Sciences UK, Ltd.

What is being bought

Published requirement description

Nice guidelines recommend Endopredict, Oncotype DX or Prosigna Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Of these 3 tests it has been confirmed that Oncotype DX is the only one available under the framework, Contract Ref. Pathology and Point of Care Testing, Associated Equipment, Instruments, Consumables and Accessories and Managed Services (2019/S 212-519575). A direct award has been made to Exact Sciences for Oncotype DX for the following reason: Specialist expertise is required and only available from one source.

CPV: Diagnostic supplies

The lotProcurement structure

single lot · no lot value published

Lot #1Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerAwarded

Delivery: South West · TORBAY HOSPITAL

33124130 Diagnostic supplies

Procedure terms & legal framework

From the official record

Procedure method: Award procedure without prior publication of a call for competition
Legal basis: CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
Procurement category: Goods
Notice status: Awarded without competition
Procurement threshold: Unspecified in notice
Regulatory regime: Standard
Commercial structure: Stand-alone contract (no framework)
Competition type: Direct award (no call for competition)
GPA / WTO covered: Unspecified in notice
Recurring procurement: Unspecified in notice
First published: 26 Apr 2022, 16:39 BST
Last source update: 26 Apr 2022, 16:39 BST
Authority reference: LOCCON454
FTS notice number: 2022/S 000-010759
Classification (CPV): Diagnostic supplies
Delivery area: South West (UKK42)
Official registry OCID: ocds-h6vhtk-0330a5 Find a Tender

Why no open competition: The procurement falls outside the scope of application of the directive
Published justification: Nice guidelines recommend Endopredict, Oncotype DX or Prosigna Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer. Of these 3 tests it has been confirmed that Oncotype DX is the only one available under the framework, Contract Ref. Pathology and Point of Care Testing, Associated Equipment, Instruments, Consumables and Accessories and Managed Services (2019/S 212-519575). A direct award has been made to Exact Sciences for Oncotype DX for the following reason: Specialist expertise is required and only available from one source.

Commercial outcome & contract awards

Published awards, contracts and bid statistics, not a forecast

Awards 1

Awarded value £121,5001 contract exc. VAT

Bids received 1

Contracts signed 1latest 17 Mar 2022

Awarded to	Value	Date	Status
Exact Sciences UK, Ltd.	£121,500 †	—	Awarded

Contracts

PROVISION OF TUMOUR PROFILING TEST · Exact Sciences UK, Ltd.
Signed
17 Mar 2022
Value
£121,500
Status
active

Bid statistics published by the authority

Bids	SME	VCSE	Valid bid range
1bids	—	—	—

Contracting authority & participating public bodies

NHS South West - Acutes

Contracting authorityCentral GovernmentRegional or local authorityHealth 1234 Acute Trusts, Torquay , South West, South west regionContact name, email, phone

Dispute resolution & review bodies

TORBAY & SOUTH DEVON NHS FOUNDATION TRUSTMediation bodyReview bodyReview contact point TORQUAY Contact email

Bidders & participating suppliers

1 commercial party on the notice

EXACT SCIENCES UK LTDAwarded supplier7484560 3 LAVINGTON STREET , LONDON , UK, SE1 ONZ Contact email, phone

Official documents & specifications

Official links; attachments are not copied

No document links were published on the notice.